Why the study?
Does stopping renin-angiotensin system inhibitors after hyperkalemia affect the risk of adverse outcomes?
Does stopping renin-angiotensin system inhibitors after hyperkalemia affect the risk of adverse outcomes?
Stopping RASi after hyperkalemia is associated with a trade-off between reduced recurrent hyperkalemia and increased risk of death and cardiovascular events.
Supports caution with RASi discontinuation after hyperkalemia; leaves open optimal strategies for RCTs.
These findings suggest that stopping RASi after hyperkalemia may be associated with a lower risk of recurrence of hyperkalemia, but higher risk of death and cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: